12.99  0.05 (0.39%)		05-16 14:04
Open: 13 High: 13 Volume: 2,123,947		Pre. Close: 12.94 Low: 12.795 Market Cap: 6,451(M)

Short term
Mid term
Targets	6-month :	15.42	1-year :	18.01
Resists	First :	13.2	Second :	15.42
Pivot price	11.19
Supports	First :	10	Second :	8.02
MAs	MA(5) :	12.92	MA(20) :	10.67
	MA(100) :	10.92	MA(250) :	12.96
MACD	MACD :	0.9	Signal :	0.5
%K %D	K(14,3) :	93	D(3) :	93.9
RSI	RSI(14): 73.3
52-week	High :	18.79	Low :	8.02

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ELAN ] has closed below upper band by 21.3%. Bollinger Bands are 258.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	13 - 13.07	13.07 - 13.12
Low:	12.51 - 12.58	12.58 - 12.65
Close:	12.82 - 12.93	12.93 - 13.04

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Fri, 16 May 2025
Elanco to Participate in the Upcoming Investor Conferences | ELAN Stock News - GuruFocus

Fri, 16 May 2025
Elanco Leadership Takes Center Stage: Key Updates Coming at BNP Paribas and Stifel Conferences - Stock Titan

Fri, 16 May 2025
Elanco to Participate in the Upcoming Investor Conferences - PR Newswire

Mon, 12 May 2025
Elanco: Deleveraging Takes Time (NYSE:ELAN) - Seeking Alpha

Sat, 10 May 2025
Elanco Animal Health Incorporated Just Recorded A 117% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance

Fri, 09 May 2025
Elanco Animal Health Incorporated (NYSE:ELAN) Q1 2025 Earnings Call Transcript - Insider Monkey

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	497 (M)
Shares Float	493 (M)
Held by Insiders	1 (%)
Held by Institutions	100.2 (%)
Shares Short	24,810 (K)
Shares Short P.Month	16,330 (K)

EPS	0.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	12.32
Profit Margin	8.4 %
Operating Margin	10.1 %
Return on Assets (ttm)	1.1 %
Return on Equity (ttm)	6 %
Qtrly Rev. Growth	-1 %
Gross Profit (p.s.)	4.89
Sales Per Share	8.91
EBITDA (p.s.)	1.73
Qtrly Earnings Growth	116.6 %
Operating Cash Flow	535 (M)
Levered Free Cash Flow	1,320 (M)

PE Ratio	17.28
PEG Ratio	0
Price to Book value	1.05
Price to Sales	1.45
Price to Cash Flow	12.03

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.